243 related articles for article (PubMed ID: 22947364)
1. The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension.
Chrysant SG; Chrysant GS
J Clin Hypertens (Greenwich); 2012 Sep; 14(9):644-9. PubMed ID: 22947364
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
Chrysant SG
Curr Hypertens Rep; 2013 Oct; 15(5):475-83. PubMed ID: 23917809
[TBL] [Abstract][Full Text] [Related]
3. [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Liu Y
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1147-51. PubMed ID: 24432631
[TBL] [Abstract][Full Text] [Related]
4. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
5. [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G; Flüchter S; Kirstein M; Kunz T
Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
8. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
9. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
10. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Ioakeimidis N; Kostis JB
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
[TBL] [Abstract][Full Text] [Related]
12. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
13. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Rosen RC; McKenna KE
Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
15. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
16. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
17. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.
Tzoumas N; Farrah TE; Dhaun N; Webb DJ
Br J Pharmacol; 2020 Dec; 177(24):5467-5488. PubMed ID: 31721165
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibition in essential hypertension.
Ghiadoni L; Versari D; Taddei S
Curr Hypertens Rep; 2008 Feb; 10(1):52-7. PubMed ID: 18367027
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Arif SA; Poon H
Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions.
Schwartz BG; Jackson G; Stecher VJ; Campoli-Richards DM; Kloner RA
Am J Med; 2013 Mar; 126(3):192-9. PubMed ID: 23410557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
